PARIS (Reuters) – French vaccine company Valneva and U.S. drugmaker Pfizer announced on Tuesday more positive Phase 2 results, including on the booster response, for their Lyme disease vaccine candidate VLA15.
“We are excited by these additional Phase 2 results, which we believe take us a step closer to making a major contribution against this severe disease, subject to regulatory approval,” said Valneva’s chief medical officer Juan Carlos Jaramillo.
(Reporting by Sudip Kar-Gupta; Editing by Kim Coghill)
